Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy

Open Access 01-03-2024 | Myasthenia Gravis | ORIGINAL RESEARCH

Constructing and Validating a Nomogram Model for Short-Term Prognosis of Patients with AChR-Ab+ GMG

Authors: Feng Liang, Zhaoxu Yin, Yaqian Li, Guanxi Li, Jing Ma, Huiqiu Zhang, Xiaoqian Xia, Make Yao, Xiaomin Pang, Juan Wang, Xueli Chang, Junhong Guo, Wei Zhang

Published in: Neurology and Therapy

Login to get access

Abstract

Objective

This study aimed to establish and validate a nomogram prognostic model for predicting short-term efficacy of acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (GMG).

Methods

A retrospective observational study was conducted at the First Hospital of Shanxi Medical University, enrolling patients diagnosed with AChR-Ab+ GMG from May 2020 to September 2022. The primary outcome was the change in the Myasthenia Gravis Foundation of America (MGFA) post-intervention status after 6 months of standard treatment. Predictive factors were identified through univariate and multivariate logistic regression analyses, with significant factors incorporated into the nomogram. The bootstrap test was used for internal validation of the nomogram model. Model performance was assessed using calibration curves, receiver-operating characteristic curve analysis, and decision curve analysis (DCA).

Results

A total of 90 patients were enrolled, of whom 30 achieved unchanged or worse status after 6 months of standard therapy. Univariate logistic regression analysis showed that quantitative myasthenia gravis score, gender, body mass index, course of disease, hemoglobin levels, and white blood cell counts were six potential predictors. These factors were used for multivariate logistic regression analysis, and a nomogram was constructed. The calibration curve showed that the predicted value was in good agreement with the actual value (p = 0.707), and the area under the curve value (0.792, 95% CI 0.686–0.899) indicated good discrimination ability. DCA suggests that this model has potential clinical application value.

Conclusion

The constructed nomogram, based on key patient indicators, shows promise as a clinically useful tool for predicting the short-term efficacy of treatment of AChR-Ab+ GMG. Validation in larger, multicenter cohorts is needed to further substantiate its applicability.
Appendix
Available only for authorised users
Literature
1.
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36.CrossRefPubMed
2.
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.CrossRefPubMed
3.
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.CrossRefPubMedPubMedCentral
4.
Mahic M, Bozorg A, DeCourcy J, Golden K, Gibson G, Taylor C, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169.CrossRefPubMedPubMedCentral
5.
Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167–78.CrossRefPubMed
6.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–25.CrossRefPubMedPubMedCentral
7.
8.
Geng Y, Zhang H, Wang Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients: a meta-analysis: erratum. Medicine. 2020;99(1): e18622.CrossRefPubMedPubMedCentral
9.
Alqarni F, Almalki D, Aljohani Z, Ali A, AlSaleem A, Alotaibi N, et al. Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy. Neurosciences (Riyadh, Saudi Arabia). 2021;26(1):4–14.CrossRefPubMed
10.
Chen K, Li Y, Yang H. Poor responses and adverse outcomes of myasthenia gravis after thymectomy: predicting factors and immunological implications. J Autoimmun. 2022;132: 102895.CrossRefPubMed
11.
Zhao R, Wang Y, Huan X, Zhong H, Zhou Z, Xi J, et al. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. J Transl Med. 2021;19(1):285.CrossRefPubMedPubMedCentral
12.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23.CrossRefPubMed
13.
Yoshimoto Y, Ishida S, Hosokawa T, Arawaka S. Assessment of clinical factors affecting outcome of myasthenia gravis. Muscle Nerve. 2021;64(1):90–4.CrossRefPubMed
14.
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflamm. 2022;19(1):89.CrossRef
15.
Zhong H, Ruan Z, Yan C, Lv Z, Zheng X, Goh LY, et al. Short-term outcome prediction for myasthenia gravis: an explainable machine learning model. Ther Adv Neurol Disord. 2023;16:17562864231154976.CrossRefPubMedPubMedCentral
16.
Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. Annali dell’Istituto superiore di sanita. 2016;52(2):205–12.PubMed
17.
Wilcke H, Glaubitz S, Kück F, Anten C, Liebetanz D, Schmidt J, et al. Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study. BMC Neurol. 2023;23(1):366.CrossRefPubMedPubMedCentral
18.
Katzberg HD, Barnett C, Bril V. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve. 2012;45(5):648–52.CrossRefPubMed
19.
Liberski PS, Szewczyk M, Krzych ŁJ. Haemogram-derived indices for screening and prognostication in critically ill septic shock patients: a case-control study. Diagnostics (Basel, Switzerland). 2020;10(9):638.PubMedPubMedCentral
20.
Gunaldi M, Goksu S, Erdem D, Gunduz S, Okuturlar Y, Tiken E, et al. Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study. Int J Clin Exp Med. 2015;8(4):5937–42.PubMedPubMedCentral
21.
Halazun HJ, Mergeche JL, Mallon KA, Connolly ES, Heyer EJ. Neutrophil-lymphocyte ratio as a predictor of cognitive dysfunction in carotid endarterectomy patients. J Vasc Surg. 2014;59(3):768–73.CrossRefPubMedPubMedCentral
22.
Hsu CW, Chen NC, Huang WC, Lin HC, Tsai WC, Huang CC, et al. Hemogram parameters can predict in-hospital mortality of patients with myasthenic crisis. BMC Neurol. 2021;21(1):388.CrossRefPubMedPubMedCentral
23.
Yang DH, Qian MZ, Wei MM, Li J, Yu MM, Lu XM, et al. The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis. Oncotarget. 2017;8(44):76099–107.CrossRefPubMedPubMedCentral
24.
Jiang Z, Ning Z, Yang L, Chen B, Tang J, Zhang J, et al. The correlation of neutrophil-to-lymphocyte ratio with the presence and short-time curative effect of myasthenia gravis in children: a retrospectively study. Int J Neurosci. 2021;131(9):894–901.CrossRefPubMed
25.
Duan Z, Jia A, Cui W, Feng J. Correlation between neutrophil-to-lymphocyte ratio and severity of myasthenia gravis in adults: a retrospective study. J Clin Neurosci. 2022;106:117–21.CrossRefPubMed
26.
Hao Z, Wu B, Wang D, Lin S, Tao W, Liu M. A cohort study of patients with anemia on admission and fatality after acute ischemic stroke. J Clin Neurosci. 2013;20(1):37–42.CrossRefPubMed
27.
Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, Martínez-Ortiz ML, Molins E, Serra P, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9(3):243–50.CrossRefPubMed
28.
Sekiguchi K, Ishizuchi K, Takizawa T, Motegi H, Oyama M, Nakahara J, et al. Anemia in female patients with myasthenia gravis. PLoS ONE. 2022;17(9): e0273720.CrossRefPubMedPubMedCentral
29.
Shi J, Huan X, Zhou L, Xi J, Song J, Wang Y, et al. Comorbid autoimmune diseases in patients with myasthenia gravis: a retrospective cross-sectional study of a Chinese cohort. Front Neurol. 2021;12: 790941.CrossRefPubMedPubMedCentral
30.
Lv Z, Zhong H, Huan X, Song J, Yan C, Zhou L, et al. predictive score for in-hospital mortality of myasthenic crisis: a retrospective Chinese cohort study. Eur Neurol. 2019;81(5–6):287–93.CrossRefPubMed
31.
Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Shiraishi A. Low hemoglobin levels are associated with sarcopenia, dysphagia, and adverse rehabilitation outcomes after stroke. J Stroke Cerebrovasc Dis. 2020;29(12): 105405.CrossRefPubMed
32.
Kim KH, Kim SW, Cho J, Chung HY, Shin HY. Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis. Front Neurol. 2022;13: 978997.CrossRefPubMedPubMedCentral
33.
Tang YL, Ruan Z, Su Y, Guo RJ, Gao T, Liu Y, et al. Clinical characteristics and prognosis of very late-onset myasthenia gravis in China. Neuromusc Disord NMD. 2023;33(4):358–66.CrossRefPubMed
Metadata
Title
Constructing and Validating a Nomogram Model for Short-Term Prognosis of Patients with AChR-Ab+ GMG
Authors
Feng Liang
Zhaoxu Yin
Yaqian Li
Guanxi Li
Jing Ma
Huiqiu Zhang
Xiaoqian Xia
Make Yao
Xiaomin Pang
Juan Wang
Xueli Chang
Junhong Guo
Wei Zhang
Publication date
01-03-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00590-0